Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Diabetes and Endocrinology
  • Diabetes and Endocrinology News
  • SGLT-2 inhibitors...

SGLT-2 inhibitors better than DPP-4 inhibitors in frail diabetes patients

Dr. Hiral patelWritten by Dr. Hiral patel Published On 2022-08-09T12:00:29+05:30  |  Updated On 2022-08-09T15:20:24+05:30
SGLT-2 inhibitors better than DPP-4 inhibitors in frail diabetes patients

Australia: Sodium-glucose cotransporter-2 inhibitors may be preferred to dipeptidyl peptidase-4 inhibitors for reducing rates of major adverse cardiovascular events, heart failure hospitalizations, and all-cause mortality in frail people with type 2 diabetes, states an article published in the Frontiers in Pharmacology.FDA-approved Sodium-glucose cotransporter-2 inhibitors (SGLT-2Is)...

Australia: Sodium-glucose cotransporter-2 inhibitors may be preferred to dipeptidyl peptidase-4 inhibitors for reducing rates of major adverse cardiovascular events, heart failure hospitalizations, and all-cause mortality in frail people with type 2 diabetes, states an article published in the Frontiers in Pharmacology.

FDA-approved Sodium-glucose cotransporter-2 inhibitors (SGLT-2Is) are prescribed to lower blood sugar in adults with type 2 diabetes. Studies have shown that SGLT2 inhibitors are also beneficial in reducing heart failure (HF) hospitalizations and major adverse cardiovascular events (MACE) in general type 2 diabetes populations. However, those with frailty are typically excluded from the studies despite their high prevalence of diabetes. There is increasing interest in whether treatment benefits and risks in general older populations can be extended to frail people.

Frailty is a medical condition closely related to diabetes and a risk factor for diabetes-related complications. Frail people have over 5-times higher odds of hospitalization and a 35% increased risk of mortality compared to non-frail individuals with diabetes. SGLT-2Is and dipeptidyl peptidase-4 inhibitors may be preferred over sulfonylureas and insulin in people at high risk of hypoglycemia such as those who are frail. It remains unclear whether SGLT-2Is or DPP-4Is have the same benefits and risks in frail people with type 2 diabetes compared to non-frail people with type 2 diabetes.

Wood S, Monash University, Australia and colleagues conducted a study to determine whether SGLT-2Is vs. dipeptidyl peptidase-4 inhibitors (DPP-4Is) are associated with reductions in MACE, HF hospitalizations, and mortality in frail people with type 2 diabetes.

Researchers included 32,043 patients, (aged ≥30 years) with type 2 diabetes discharged from a hospital in the cohort. They received SGLT-2Is or DPP-4Is within 60 days of discharge. Follow-up commenced 60 days after initial discharge, and MACE, HF hospitalization, and mortality were recorded. Analyses were stratified into frailty quartiles according to Hospital Frailty Risk Scores(HFRSs). Cox proportional hazards regression with competing risks and stabilized inverse probability of treatment weights (IPTWs), was used to generate subdistribution hazard ratios (sHRs)

Key findings of the study,

• Overall, SGLT-2I versus DPP-4I recipients had lower rates of MACE (sHR 0.51), HF hospitalization (sHR 0.42), and mortality (HR 0.38).

• People with HFRSs in the fourth quartile who received SGLT-2Is versus DPP-4Is also had reduced rates of MACE (sHR 0.37), HF hospitalization (sHR 0.43), and mortality (HR 0.32).

The authors conclude that study provides preliminary evidence to suggest that SGLT-2Is may be preferred to DPP-4Is in the treatment of frail people living with type 2 diabetes as it showed a reduced rate of MACE, HF hospitalizations, and all-cause mortality. These findings may help the development of updated type 2 diabetes clinical practice guidelines.

Reference:

Wood SJ, Bell JS, Magliano DJ, Shaw JE, Cesari M, Ilomaki J. Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized. Front Pharmacol. 2022 Jul 12;13:886834. doi: 10.3389/fphar.2022.886834. 

Frontiers in Pharmacology Sodium-glucose cotransporter-2 inhibitors dipeptidyl peptidase-4 inhibitors frail type 2 diabetes major adverse cardiovascular events heart failure 
Source : Frontiers in Pharmacology
Dr. Hiral patel
Dr. Hiral patel

    BDS

    Dr. Hiral patel (BDS) has completed BDS from Gujarat University, Baroda. She has worked in private dental steup for 8years and is currently a consulting general dentist in mumbai. She has recently completed her advanced PG diploma in clinical research and pharmacovigilance. She is passionate about writing and loves to read, analyses and write informative medical content for readers. She can be contacted at editorial@medicaldialogues.in.

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
    X
    X